Concepedia

Nate H. Wallace

NH

Statistics

Publications

3

Citations

174

H-Index

3

Active since

2011

Affiliations

Worldwide Clinical Trials (United States)(Current)

Nate H. Wallace is an author at Worldwide Clinical Trials (United States) specializing in medicine, jak inhibitor therapy, and cytokine biology.

Publications per year

2011–2012

3

Publications

3

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Lily Lu, Kristine L. Stump, Nate H. Wallace et al. · The Journal of Immunology · 2011 · 75 citations · Full text

, , +16

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

Matthew M. Seavey, Lily Lu, Kristine L. Stump et al. · International Immunopharmacology · 2011 · 58 citations

, , +16

Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-Induced Colorectal Cancer

Matthew M. Seavey, Lily Lu, Kristine L. Stump et al. · Molecular Cancer Therapeutics · 2012 · 41 citations

, , +17

1–3 of 3